Annalisa Lattanzi

List of Publications by Year in descending order

16 papers	691 citations	932766 10 h-index	1125271 13 g-index
16 all docs	16 docs citations	16 times ranked	1071 citing authors

#	Article	IF	Citations
1	Development of Î²-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. Science Translational Medicine, 2021, 13, .	5.8	82
2	Clinically relevant gene editing in hematopoietic stem cells for the treatment of pyruvate kinase deficiency. Molecular Therapy - Methods and Clinical Development, 2021, 22, 237-248.	1.8	11
3	Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements. Molecular Therapy, 2019, 27, 137-150.	3.7	97
4	Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human Î²-globin locus. Blood, 2018, 131, 1960-1973.	0.6	156
5	Correction of the Exon 2 Duplication in DMD Myoblasts by a Single CRISPR/Cas9 System. Molecular Therapy - Nucleic Acids, 2017, 7, 11-19.	2.3	44
6	Efficacy and biodistribution analysis of intracerebroventricular administration of an optimized scAAV9-SMN1 vector in a mouse model of spinal muscular atrophy. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16060.	1.8	41
7	Pervasive supply of therapeutic lysosomal enzymes in the <scp>CNS</scp> of normal and Krabbeâ€affected nonâ€human primates by intracerebral lentiviral gene therapy. EMBO Molecular Medicine, 2016, 8, 489-510.	3.3	50
8	135. Optimization of Dual-gRNA Lentiviral Vectors for Targeted Genomic Deletions. Molecular Therapy, 2016, 24, S55.	3.7	0
9	559. Induction of Fetal Hemoglobin in Adult Erythroblasts by Genome Editing of the Beta-Globin Locus. Molecular Therapy, 2016, 24, S223-S224.	3.7	0
10	Re-Creating Hereditary Persistence of Fetal Hemoglobin (HPFH) to Treat Sickle Cell Disease (SCD) and Î²-Thalassemia. Blood, 2016, 128, 4708-4708.	0.6	2
11	Induction of Fetal Hemoglobin Synthesis By Crispr/Cas9-Mediated Disruption of the Î²-Globin Locus Architecture. Blood, 2016, 128, 321-321.	0.6	2
12	131. Targeted Genome Editing in Spinal Muscular Atrophy. Molecular Therapy, 2015, 23, S53-S54.	3.7	0
13	Therapeutic benefit of lentiviral-mediated neonatal intracerebral gene therapy in a mouse model of globoid cell leukodystrophy. Human Molecular Genetics, 2014, 23, 3250-3268.	1.4	56
14	Dynamic Activity of miR-125b and miR-93 during Murine Neural Stem Cell Differentiation In Vitro and in the Subventricular Zone Neurogenic Niche. PLoS ONE, 2013, 8, e67411.	1.1	30
15	Widespread enzymatic correction of CNS tissues by a single intracerebral injection of therapeutic lentiviral vector in leukodystrophy mouse models. Human Molecular Genetics, 2010, 19, 2208-2227.	1.4	77
16	Specific Determination of Î²-Galactocerebrosidase Activity via Competitive Inhibition of Î²-Galactosidase. Clinical Chemistry, 2009, 55, 541-548.	1.5	43